Menu

Research Portfolio

Research Portfolio

The Cannabis Science Research Foundation currently has a number of different cannabinoid formulations in development including CS-NEURO-1, CS-S/BCC-1 and CS-TATI-1.

CS-NEURO-1
In 2013, we submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders". The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety. The first formulation of CS-NEURO-1 in the series of neurobehavioral disorder-targeted products is in pre-clinical development with promising results.  We intend to use the invention in food products through a licensing agreement with a partner company and move forward contemporaneously with pharmaceutical grade development in Europe and North America.

CS-S/BCC-1
Since 2011, we have seen apparent success in 4 skin cancer patients who have self-administered CS-S/BCC-1 –cannabinoid based extracts topically to their basal and squamous cell carcinomas. These patients have experienced shrinking and apparent eradication of their skin cancer lesions, backed by positive reports from their doctors. With these results, the Foundation is confident it can begin programs for over the counter (OTC) and prescription drug markets. The company is consulting with a team of FDA specialists to plan for a pre-IND meeting with the agency with the goal of creating a road map leading to an IND application.

CS-TATI-1
Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2).

The Foundation's development of CS-TATI-1 will be targeted to both newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of currently available therapies. Cannabis Science Research Foundation will be pursuing a wide range of NIH based Federal Research Programs such as RO1s, PO1s and SBIRs which exist to support preclinical development of target validation and proof of concept studies. The Foundation will be pursing implementation of these studies through collaborations with leading scientific institutions. The Foundation will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).